Mitochondria, prostate cancer, and biopsy sampling error

Discovery Medicine

Volumn 15, Issue 83, 2013, Pages 213-220

  Parr, Ryan L ^a   Mills, John ^b   Harbottle, Andrew ^c   Creed, Jennifer M ^d   Crewdson, Greg ^e   Reguly, Brian ^a   Guimont, François S ^a  

^a Mitomics Inc   (Canada)

^b Tissupath Pty Ltd   (Australia)

^c Mitomics Inc   (United Kingdom)

^d Mitomics   (United States)

^e Des Moines University College of Osteopathic Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; PROSTATE SPECIFIC ANTIGEN; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL PROLIFERATION; DIAGNOSTIC ERROR; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; MITOCHONDRIAL GENOME; MITOCHONDRION; MUTATION; NEEDLE BIOPSY; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; REPRODUCIBILITY;

BIOPSY, NEEDLE; CELL PROLIFERATION; DIAGNOSTIC ERRORS; DNA, MITOCHONDRIAL; GENOME, MITOCHONDRIAL; HUMANS; MALE; MITOCHONDRIA; MUTATION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; REPRODUCIBILITY OF RESULTS;

EID: 84886296087     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25(1):3-9, 2007.
2. Barringer BS. Carcinoma of the Prostate. Surg Gynec Obstetrics 2(34):168-176, 1922.
3. Chen EI. Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr 44(6):619-622, 2012.
4. Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res 62(22):6470-6474, 2002.
5. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 278(38):36027-36031, 2003.
6. Cook CC, Higuchi M. The awakening of an advanced malignant cancer: an insult to the mitochondrial genome. Biochim Biophys Acta 1820(5):652-662, 2012.
7. Corcoran NM, Hovens CM, Hong MK, Pedersen J, Casey RG, Connolly S, Peters J, Harewood L, Gleave ME, Goldenberg SL, Costello AJ. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 109(5):660-664, 2012.
8. Desouki MM, Geradts J, Milon B, Franklin RB, Costello LC. hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. Mol Cancer 6:37, 2007.
9. Falzarano SM, Zhou M, Hernandez AV, Moussa AS, Jones JS, Magi-Galluzzi C. Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology 76(3):682-687, 2010.
10. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158(2):505-508; discussion 508-509, 1997.
11. Franklin RB, Costello LC. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 463(2):211-217, 2007.
12. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176(4 Pt 1):1404-1408, 2006.
13. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, Threatte G, Korets R, Lilja H, De La Roza G. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99(19):1484-1489, 2007.
14. Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y, Shirakawa T, Sawyer JR, Gotoh A. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 25(10):1437-1445, 2006.
15. Hopper KD. Percutaneous, radiographically guided biopsy: a history. Radiology 196(2):329-333, 1995.
16. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320(5876):661-664, 2008.
17. Jessie BC, Sun CQ, Irons HR, Marshall FF, Wallace DC, Petros JA. Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages. Exp Gerontol 37(1):169-174, 2001.
18. Johenning PW. A history of aspiration biopsy with special attention to prostate biopsy. Diagn Cytopathol 4(3):265-268, 1988.
19. Kelsey DM, Kohler FP, Mackinney CC, Kline TS. Outpatient needle aspiration biopsy of the prostate. J Urol 116(3):327-328, 1976.
20. Krishnan KJ, Reeve AK, Samuels DC, Chinnery PF, Blackwood JK, Taylor RW, Wanrooij S, Spelbrink JN, Lightowlers RN, Turnbull DM. What causes mitochondrial DNA deletions in human cells. Nat Genet 40(3):275-279, 2008.
21. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68(6):1777-1785, 2008.
22. Lawrentschuk N, Toi A, Lockwood GA, Evans A, Finelli A, O'malley M, Margolis M, Ghai S, Fleshner NE. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol 182(6):2659-2663, 2009.
23. Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A, Diamandis EP, Escott N, Skehan A, Prowse O, Thayer RE, Froberg MK, Wilson MJ, Maragh S, Jakupciak JP, Wagner PD, Srivastava S, Dakubo GD, Parr RL. Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol 129(1):57-66, 2008.
24. Mills J, Guimont F, Reguly B, Harbottle a, Creed J, Parr R. Large-scale 3.4kb mitochondrial deletion is significantly associated with a prostate cancer field effect. 2013.
25. Mimaki M, Wang X, Mckenzie M, Thorburn DR, Ryan MT. Understanding mitochondrial complex I assembly in health and disease. Biochim Biophys Acta 1817(6):851-862, 2012.
26. Mita S, Rizzuto R, Moraes CT, Shanske S, Arnaudo E, Fabrizi GM, Koga Y, Dimauro S, Schon EA. Recombination via flanking direct repeats is a major cause of large-scale deletions of human mitochondrial DNA. Nucleic Acids Res 18(3):561-567, 1990.
27. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 417(1):1-13, 2009.
28. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, Lechleiter J, Naylor SL, Deng JJ, Lu J, Bai Y. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet 18(9):1578-1589, 2009.
29. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittock R, Robinson K, Alexander JS, Birch-Machin MA, Abdel-Malak M, Froberg MK, Diamandis EP, Thayer RE. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 8(3):312-319, 2006.
30. Parr RL, Martin LH. Mitochondrial and nuclear genomics and the emergence of personalized medicine. Hum Genomics 6(1):3, 2012.
31. Pereira L, Soares P, Maximo V, Samuels DC. Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors. BMC Cancer 12:53, 2012.
32. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 102(3):719-724, 2005.
33. Reinisch H. [A new biopsy device (author's transl)]. Arch Geschwulstforsch 47(7):611-615, 1977.
34. Reziciner S. [Transrectal biopsy of the prostate with a cutting needle]. J Urol Nephrol (Paris) 83(1-2):85-87, 1977.
35. Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D, Maggrah A, Klotz L, Parr RL, Dakubo GD. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 13(2):126-131, 2010.
36. Sciacco M, Bonilla E, Schon EA, Dimauro S, Moraes CT. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 3(1):13-19, 1994.
37. Sinnott M, Falzarano SM, Hernandez AV, Jones JS, Klein EA, Zhou M, Magi-Galluzzi C. Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: implications for focal therapy. Prostate 72(11):1179-1186, 2012.
38. Torlakovic G, Grover VK, Torlakovic E. Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume. Croat Med J 46(3):423-428, 2005.
39. Trujillo KA, Jones AC, Griffith JK, Bisoffi M. Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Cancer 2012:302894, 2012.